MENLO PARK, Calif., April 7, 2021 /PRNewswire/ — Synthego, the genome engineering firm, right this moment introduced the launch of Eclipse™, a brand new high-throughput cell engineering platform designed to speed up drug discovery and validation by offering extremely predictable CRISPR-engineered cells at scale by means of the combination of engineering, bioinformatics, and proprietary science. The launch of this distinctive CRISPR-based platform is driving the corporate’s rising affect in biopharma R&D, reinforcing Synthego’s place because the genome engineering chief. 

CRISPR-engineered cells have a variety of purposes in analysis and improvement throughout illness areas, together with in neuroscience and oncology. Synthego created the Eclipse platform to improve illness modeling, drug goal identification and validation, and speed up cell remedy manufacturing.

“By industrializing cell engineering, Synthego’s Eclipse platform will enable economies of scale, turning a historically complex process into one that is flexible, reliable, and affordable,” mentioned Bill Skarnes, Ph.D., professor and director of Cellular Engineering at The Jackson Laboratory and Synthego advisory board member. “Offering CRISPR edits at scale, similar to what Synthego did with sgRNA reagents, puts researchers on the cusp of being able to study thousands of genes, and examine hundreds of variants of those genes. This will allow scientists to more faithfully model the complexity of a human disease, which could lead to the development of therapeutic drugs or next-generation gene therapies for many serious diseases.”

To make sure the success of any sort of edit, Eclipse makes use of machine studying to apply expertise from a number of hundred thousand genome edits throughout a whole lot of cell varieties. With this machine studying, mixed with automation, the brand new platform can cut back prices and enhance the scalability of engineered cell manufacturing. The Eclipse platform is modular in design, permitting for quick deployment of upgrades or add-ons. It is engineered to use a cell-type agnostic course of and instantly profit researchers working with induced pluripotent stem (iPS) cells and immortalized cell traces. 

“We are living in a new era of life sciences innovation – one that has added to DNA sequencing and being able to read out of biology, now being able to write into and engineer biology. We created our Eclipse platform at the convergence of science and technology to make genome editing more precise, scalable, and accessible,” mentioned Paul Dabrowski, CEO and co-founder of Synthego. “We are excited to expand our impact on advancing the life sciences innovation with the launch of this unique CRISPR-based platform.”

For additional details about Eclipse, go to  

About Synthego
Synthego is a genome engineering firm that permits the acceleration of life science analysis and improvement within the pursuit of improved human well being. The firm leverages machine studying, automation, and gene enhancing to construct platforms for science at scale. With its foundations in engineering disciplines, the corporate’s platforms vertically combine proprietary {hardware}, software program, bioinformatics, chemistries, and molecular biology to advance each fundamental analysis and therapeutic improvement applications. With its applied sciences cited in a whole lot of peer-reviewed publications and utilized by hundreds of business and educational researchers and therapeutic drug builders, Synthego is on the forefront of innovation enabling the subsequent technology of medicines by delivering genome enhancing at an unprecedented scale.

SOURCE Synthego

Related Links


Leave a Reply

Your email address will not be published. Required fields are marked *